Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Celsion Corporation    CLSN

CELSION CORPORATION

(CLSN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

CELSION CORP : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)

10/16/2020 | 05:00pm EST

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On October 13, 2020, Celsion Corporation ("we," "our," "us," "Celsion," or "the Company") received notice from The Nasdaq Stock Market ("Nasdaq") that the closing bid price for our common stock had been below $1.00 per share for the previous 30 consecutive business days, and that we are therefore not in compliance with the minimum bid price requirement for continued inclusion on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the "Rule").

Nasdaq's notice has no immediate effect on the listing or trading of our common stock on The Nasdaq Capital Market.

The notice indicates that we will have 180 calendar days, until April 12, 2021, to regain compliance with this requirement. We can regain compliance with the $1.00 minimum bid listing requirement if the closing bid price of our common stock is at least $1.00 per share for a minimum of ten (10) consecutive business days during the 180-day compliance period. If we do not regain compliance during the initial compliance period, we may be eligible for additional time to regain compliance. To qualify, we will be required to meet the continued listing requirement for market value of our publicly held shares and all other Nasdaq initial listing standards, except the bid price requirement, and will need to provide written notice to Nasdaq of our intention to cure the deficiency during the second compliance period. If we meet these requirements, we expect that Nasdaq will grant us an additional 180 calendar days to regain compliance with the minimum bid price requirement. If it appears to Nasdaq that we will not be able to cure the deficiency, or if we are otherwise not eligible, we expect that Nasdaq will notify us that our common stock will be subject to delisting. We will have the right to appeal a determination to delist our common stock, and our common stock would remain listed on The Nasdaq Capital Market until the completion of the appeal process.

We intend to actively monitor the minimum bid price of our common stock and may, as appropriate, consider available options to regain compliance with the Rule.

© Edgar Online, source Glimpses

All news about CELSION CORPORATION
11/16CELSION : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULT..
AQ
11/16CELSION CORP : Results of Operations and Financial Condition, Financial Statemen..
AQ
11/16CELSION CORPORATION : Reports Third Quarter 2020 Financial Results and Provides ..
AQ
11/16Celsion Corporation Reports Third Quarter 2020 Financial Results and Provides..
GL
11/13CLSN SHAREHOLDER ALERT : Bronstein, Gewirtz & Grossman, LLC Notifies Celsion Cor..
BU
11/09CELSION CORPORATION : to Hold Third Quarter 2020 Financial Results and Business ..
AQ
11/09Celsion Corporation to Hold Third Quarter 2020 Financial Results and Business..
GL
11/07CELSION : ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Celsion Corporation Investors ..
BU
11/03SHAREHOLDER ACTION REMINDER : The Schall Law Firm Announces the Filing of a Clas..
BU
11/02SHAREHOLDER ACTION ALERT : The Schall Law Firm Announces the Filing of a Class A..
BU
More news
Financials (USD)
Sales 2020 0,51 M - -
Net income 2020 -22,8 M - -
Net Debt 2020 - - -
P/E ratio 2020 -0,84x
Yield 2020 -
Capitalization 22,8 M 22,8 M -
Capi. / Sales 2020 45,1x
Capi. / Sales 2021 91,0x
Nbr of Employees 29
Free-Float 98,8%
Chart CELSION CORPORATION
Duration : Period :
Celsion Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELSION CORPORATION
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 3,00 $
Last Close Price 0,61 $
Spread / Highest target 393%
Spread / Average Target 393%
Spread / Lowest Target 393%
EPS Revisions
Managers
NameTitle
Michael H. Tardugno Chairman, President & Chief Executive Officer
Jeffrey Wayne Church CFO, Secretary & SVP-Investor Relations
Nicholas Borys Chief Medical Officer & Senior Vice President
Khursheed Anwer Chief Scientific Officer & Executive VP
Pok Yu Chow Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CELSION CORPORATION-64.43%23
GILEAD SCIENCES, INC.-5.94%76 616
VERTEX PHARMACEUTICALS5.18%59 887
REGENERON PHARMACEUTICALS36.91%54 257
WUXI APPTEC CO., LTD.64.86%39 976
BIONTECH SE236.51%27 452